Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Echinococcus granulosus | mitogen activated protein kinase | 0.051 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.051 | 1 | 1 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.051 | 1 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.051 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.051 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Schistosoma mansoni | serine/threonine protein kinase | 0.051 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.051 | 1 | 1 |
Giardia lamblia | Kinase, CMGC MAPK | 0.051 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.051 | 1 | 1 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.051 | 1 | 1 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.051 | 1 | 1 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.051 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 0.0146 | 0.0146 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.0146 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.0146 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.051 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.051 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.0146 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma brucei | protein kinase, putative | 0.051 | 1 | 1 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.0146 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.051 | 1 | 1 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.051 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.0146 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.0146 | 0.0146 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.051 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.0146 | 0.0146 |
Trichomonas vaginalis | CMGC family protein kinase | 0.051 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.051 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.5481 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.